PL376607A1 - Application of antagonists oxytocin and/or vasopressin - Google Patents

Application of antagonists oxytocin and/or vasopressin

Info

Publication number
PL376607A1
PL376607A1 PL376607A PL37660705A PL376607A1 PL 376607 A1 PL376607 A1 PL 376607A1 PL 376607 A PL376607 A PL 376607A PL 37660705 A PL37660705 A PL 37660705A PL 376607 A1 PL376607 A1 PL 376607A1
Authority
PL
Poland
Prior art keywords
oxytocin
vasopressin
antagonists
application
antagonists oxytocin
Prior art date
Application number
PL376607A
Other languages
Polish (pl)
Inventor
Waldemar Kuczyński
Piotr Pierzyński
Original Assignee
Waldemar Kuczyński
Piotr Pierzyński
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Waldemar Kuczyński, Piotr Pierzyński filed Critical Waldemar Kuczyński
Priority to PL376607A priority Critical patent/PL376607A1/en
Priority to DE602006021736T priority patent/DE602006021736D1/en
Priority to AT06747719T priority patent/ATE507830T1/en
Priority to CA2605923A priority patent/CA2605923C/en
Priority to RU2007140702/15A priority patent/RU2385735C2/en
Priority to PL06747719T priority patent/PL1879572T3/en
Priority to CN2006800568367A priority patent/CN101646436B/en
Priority to EP06747719A priority patent/EP1879572B1/en
Priority to MX2007014022A priority patent/MX2007014022A/en
Priority to NZ562409A priority patent/NZ562409A/en
Priority to PT06747719T priority patent/PT1879572E/en
Priority to PCT/PL2006/000029 priority patent/WO2006121362A2/en
Priority to KR1020077025706A priority patent/KR100985449B1/en
Priority to ES06747719T priority patent/ES2366130T3/en
Priority to JP2008511075A priority patent/JP4762308B2/en
Priority to DK06747719.0T priority patent/DK1879572T3/en
Priority to AU2006244693A priority patent/AU2006244693B2/en
Priority to SI200631039T priority patent/SI1879572T1/en
Priority to US11/914,049 priority patent/US20080318847A1/en
Publication of PL376607A1 publication Critical patent/PL376607A1/en
Priority to IL186595A priority patent/IL186595A/en
Priority to NO20076328A priority patent/NO340956B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
PL376607A 2005-05-10 2005-08-12 Application of antagonists oxytocin and/or vasopressin PL376607A1 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
PL376607A PL376607A1 (en) 2005-08-12 2005-08-12 Application of antagonists oxytocin and/or vasopressin
NZ562409A NZ562409A (en) 2005-05-10 2006-05-10 Use of barusiban in assisted reproduction
KR1020077025706A KR100985449B1 (en) 2005-05-10 2006-05-10 Use of antagonists of oxytocin and/or vasopressin in assisted reproduction
CA2605923A CA2605923C (en) 2005-05-10 2006-05-10 Use of antagonists of oxytocin and/or vasopressin
RU2007140702/15A RU2385735C2 (en) 2005-05-10 2006-05-10 Application of oxytocin antagonists in assisted reproduction
PL06747719T PL1879572T3 (en) 2005-05-10 2006-05-10 Use of antagonists of oxytocin and/or vasopressin in assisted reproduction
CN2006800568367A CN101646436B (en) 2005-05-10 2006-05-10 Use of antagonists of oxytocin and/or vasopressin in assisted reproductive technology
EP06747719A EP1879572B1 (en) 2005-05-10 2006-05-10 Use of antagonists of oxytocin and/or vasopressin in assisted reproduction
MX2007014022A MX2007014022A (en) 2005-05-10 2006-05-10 Use of antagonists of oxytocin and/or vasopressin in assisted reproduction.
DE602006021736T DE602006021736D1 (en) 2005-05-10 2006-05-10 USE OF ANTAGONISTS OF OXYTOCIN AND / OR VASOPRESSIN IN ASSISTED REPRODUCTION
PT06747719T PT1879572E (en) 2005-05-10 2006-05-10 Use of antagonists of oxytocin and/or vasopressin in assisted reproduction
PCT/PL2006/000029 WO2006121362A2 (en) 2005-05-10 2006-05-10 Use of antagonists of oxytocin and/or vasopressin in assisted reproduction
AT06747719T ATE507830T1 (en) 2005-05-10 2006-05-10 USE OF ANTAGONISTS OF OXYTOCIN AND/OR VASOPRESSIN IN ASSISTED REPRODUCTION
ES06747719T ES2366130T3 (en) 2005-05-10 2006-05-10 USE OF OXYCHOCINE AND / OR VASOPRESINE ANTAGONISTS IN ASSISTED REPRODUCTION.
JP2008511075A JP4762308B2 (en) 2005-05-10 2006-05-10 Use of oxytocin and / or vasopressin antagonists in assisted reproduction
DK06747719.0T DK1879572T3 (en) 2005-05-10 2006-05-10 Use of antagonists of oxytocin and / or vasopressin in artificial insemination
AU2006244693A AU2006244693B2 (en) 2005-05-10 2006-05-10 Use of antagonists of oxytocin and/or vasopressin in assisted reproduction
SI200631039T SI1879572T1 (en) 2005-05-10 2006-05-10 Use of antagonists of oxytocin and/or vasopressin in assisted reproduction
US11/914,049 US20080318847A1 (en) 2005-05-10 2006-05-10 Use of Antagonist of Oxytocin and/or Vasopressin in Assisted Reproduction
IL186595A IL186595A (en) 2005-05-10 2007-10-11 Use of barusiban for the preparation of medicaments for an improved uterine receptivity in assisted reproduction
NO20076328A NO340956B1 (en) 2005-05-10 2007-12-10 Use of antagonists for oxytocin and / or vasopressin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL376607A PL376607A1 (en) 2005-08-12 2005-08-12 Application of antagonists oxytocin and/or vasopressin

Publications (1)

Publication Number Publication Date
PL376607A1 true PL376607A1 (en) 2007-02-19

Family

ID=43013708

Family Applications (1)

Application Number Title Priority Date Filing Date
PL376607A PL376607A1 (en) 2005-05-10 2005-08-12 Application of antagonists oxytocin and/or vasopressin

Country Status (1)

Country Link
PL (1) PL376607A1 (en)

Similar Documents

Publication Publication Date Title
IL185343A0 (en) 2-(4-oxo-4h-quinazolin-3-yl)acetamides and their use as vasopressin v3 antagonists
EP1952334A4 (en) Detection of intra-firm matching and response thereto
EP1812030A4 (en) Anti-angiogenic peptides and methods of use thereof
EP1786451A4 (en) Anti-angiogenic peptides and methods of use thereof
EP1976864A4 (en) Novel peptide and use thereof
HK1144373A1 (en) Use of fungal immunomodulatory protein
IL190217A0 (en) Combination of rosiglitazone and donepezil for improvement of cognitive function
IL185309A0 (en) Isoqunoline compounds and methods of use thereof
IS8248A (en) Replacement of tweketopiperazine and its use as oxytocin antagonists
IL182494A0 (en) Non-peptide bradykinin antagonists and pharmaceutical composition therefrom
EP1928496A4 (en) C/clp antagonists and methods of use thereof
PT2380573E (en) Eslicarbazepine acetate and methods of use
GB0505975D0 (en) Novel use of peptide
HK1161122A1 (en) Use of 24-norudca 24-norudca
EP1921066A4 (en) Pyridylphenol compound and use thereof
EP1931368A4 (en) Antifungal peptides and methods of use thereof
EP1967210A4 (en) Novel application of apelin
PL379702A1 (en) Benzamide derivatives as oxytocin agonists and vasopressin antagonists
ZA200707090B (en) 2-(4-oxo-4H-quinazolin-3-yl) acetamides and their use as vasopressin V3 antagonists
EP1931370A4 (en) Use of des-aspartate-angiotensin i
PL376607A1 (en) Application of antagonists oxytocin and/or vasopressin
ZA200802439B (en) Combination of rosiglitazone and donepezil for improvement of cognitive function
ZA200805245B (en) Combination of AXD2171 and pemetrexed
EP1805512A4 (en) Detection of bromamines and chloramines
ZA200805244B (en) Combination of ZD6474 and pemetrexed

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)